Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States

References

• Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72
   PubMed Web of Science ®Google Scholar
• Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400
   PubMed Web of Science ®Google Scholar
• Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6
   PubMed Web of Science ®Google Scholar
• VanDevanter DR, Pasta DJ, Konstan MW. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2015;14:763-9
   PubMed Web of Science ®Google Scholar
• Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62:360-7
   PubMed Web of Science ®Google Scholar
• Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011;46:870-81
   PubMed Web of Science ®Google Scholar
• Wagener JS, Rasouliyan L, VanDevanter DR, et al.; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2013;48:666-73
   PubMed Web of Science ®Google Scholar
• VanDevanter DR, Elkin EP, Pasta DJ, et al.; Investigators and Coordinators of the Epidemiologic Study of Cyst Fibrosis. Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005. J Cyst Fibros 2013;12:332-7
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Quittner AL, Fouayzi H, et al. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001–2007. Pediatr Pulmonol 2011;46:770-6
   PubMed Web of Science ®Google Scholar
• O’Sullivan AK, Sullivan J, Higuchi K, Montgomery AB. Health care utilization & costs for cystic fibrosis patients with pulmonary infections. Manag Care 2011;20:37-44
   PubMedGoogle Scholar
• Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-96
   PubMed Web of Science ®Google Scholar
• Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72
   PubMed Web of Science ®Google Scholar
• Rubin-Cahill JL, Thayer S, Waters V, et al. Frequency and costs of pulmonary exacerbations and association with % predicted FEV1 in patients with cystic fibrosis. J Cyst Fibros 2015;14(Suppl 1):S106
   Google Scholar
• Rubin-Cahill JL, Thayer S, Watkins A, et al. Lung function and health care resource utilization in patients with cystic fibrosis. J Cyst Fibros 2015;14(Suppl 1):S107
   Google Scholar
• Aurora P, Stocks J, Oliver C, et al.; on behalf of the London Cystic Fibrosis Collaboration. Quality control for spirometry in preschool children with and without lung disease. Am J Respir Crit Care Med 2004;169:1152-9
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87
   PubMed Web of Science ®Google Scholar
• Wang X, Dockery DW, Wypij D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88
   PubMed Web of Science ®Google Scholar
• Abbott J, Holt A, Hart A, et al. What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. J Cyst Fibros 2009;8:356-9
   PubMed Web of Science ®Google Scholar
• Heimeshoff M, Hollmeyer H, Schreyogg J, et al. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. PharmacoEconomics 2012;30:763-77
   PubMed Web of Science ®Google Scholar
• Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006;148:259-64
   PubMed Web of Science ®Google Scholar
• Jarad NA, Giles K. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. Chron Respir Dis 2008;5:29-33
   PubMedGoogle Scholar
• Cystic Fibrosis Foundation Patient Registry. 2013 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation, 2014. Available at: https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf [Last acessed January 18, 2017]
   Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220-31
   PubMed Web of Science ®Google Scholar
• US Department of Labor BoLS. Consumer Price Index. Medical Care. Series ID: SUUR0000SAM. Washington, DC: US Dept. of Labor, Bureau of Labor Statistics, 2012. Available at: http://data.bls.gov/cgi-bin/surveymost?su [Last accessed January 18, 2017]
   Google Scholar
• Block JK, Vandemheen KL, Tullis E, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006;61:969-74
   PubMed Web of Science ®Google Scholar
• Chevreul K, Berg Brigham K, Michel M, et al. Costs and health-related quality of life of patients with cystic fibrosis and their carers in France. J Cyst Fibros 2015;14:384-91
   PubMed Web of Science ®Google Scholar
• van Gool K, Norman R, Delatycki MB, et al. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health 2013;16:345-55
   PubMed Web of Science ®Google Scholar